Rheumatoid arthritis flare up; Heart disorder; Inflammation; This spontaneous case was reported by a consumer and describes the occurrence of RHEUMATOID ARTHRITIS (Rheumatoid arthritis flare up) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. On an unknown date, the patient experienced RHEUMATOID ARTHRITIS (Rheumatoid arthritis flare up) (seriousness criterion medically significant). an unknown date, the patient experienced CARDIAC DISORDER (Heart disorder) and INFLAMMATION (Inflammation). At the time of the report, RHEUMATOID ARTHRITIS (Rheumatoid arthritis flare up) had resolved and CARDIAC DISORDER (Heart disorder) and INFLAMMATION (Inflammation) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant products were not provided. Treatment medication were not reported. The patient had flare up with 30 minutes of receiving the covid vaccine. She felt ike heart issues and inflammation. It was unknown if patient was enrolled in a COVID 19 Vaccine Trial. The reporter's causality for the event(s) of Heart issue and Inflammation with RINVOQ(UPADACITINIB) was not provided. The reporter's causality for the event(s) of Rheumatoid arthritis flare up with RINVOQ(UPADACITINIB) was no reasonable possibility.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company comment: This is a spontaneous case reported by a consumer. An adult female patient  in treatment with UPADACITINIB (RINVOQ) for Rheumatoid arthritis, experienced medically significant event of Rheumatoid arthritis flare up (AESI) with 30 minutes of receiving first dose of mRNA-1273 vaccine. In addition, on an unknown date, she experienced non serious events of cardiac disorder and inflammation. No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. Rheumatoid arthritis can flare as part of its natural history. Rheumatoid arthritis and Upadacitinib could be contributory factors for cardiac disorder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case reported by a consumer. An adult female patient  in treatment with UPADACITINIB (RINVOQ) for Rheumatoid arthritis, experienced medically significant event of Rheumatoid arthritis flare up (AESI) with 30 minutes of receiving first dose of mRNA-1273 vaccine. In addition, on an unknown date, she experienced non serious events of cardiac disorder and inflammation. No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. Rheumatoid arthritis can flare as part of its natural history. Rheumatoid arthritis and Upadacitinib could be contributory factors for cardiac disorder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.